Existing investors WuXi PharmaTech and Mayo Clinic took part in a series B round that will help Unity Biotechnology move preclinical candidates into human trials.
Unity Biotechnology, a US-based developer of treatments for diseases related to aging, closed a $116m series B round backed by medical research companies WuXi PharmaTech and Mayo Clinic yesterday.
Financial services group Fidelity Management and Research Company also took part in the round, as did Arch Venture Partners, Baillie Gifford, Partner Fund Management, Venrock and Bezos Expeditions. Mayo Clinic invested in the round through its corporate venturing unit, Mayo Clinic Ventures.
Unity is working on drug treatments that will prevent,…
